DB18210InvestigationalProtein Based Therapies
Gresonitamab: Overview.
- Also known as
- IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN CLAUDIN 18.2) (HUMAN MONOCLONAL HWZV_KLA_L SINGLE-CHAIN VARIABLE FRAGMENT VH1-(GGGGS)3-VL1) FUSION PROTEIN WITH PEPTIDE LINKER (GGGGS) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HU
- Code names
- AMG-910
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Gresonitamab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account